Once-Daily Dose Approved for Prezista
Anti-HIV drug sanctioned in combination with ritonavir
TUESDAY, Dec. 14, 2010 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new once-daily dose for Prezista (darunavir), combined with ritonavir to treat people infected with HIV-1, a strain of the virus that causes AIDS.
In a news release, drug maker Tibotec Therapeutics said the approval was meant for adults who hadn't shown resistance to darunavir, the drug's active ingredient.
People with chronic liver disease including hepatitis or cirrhosis should be carefully monitored while taking Prezista, the company said. They also should be watched for signs of a severe skin reaction, which could include severe rash accompanied by fever, fatigue, muscle or joint pain, or blisters.
Prezista does not "cure" HIV-1 or AIDS, and will not prevent transmitting the infection to others, the drug maker stressed.
To learn more about antiviral drugs used to treat HIV infection, visit the FDA.